Emily Prendergast MD FACOG (She/Her)

Gynecologic Oncology

Associate Professor

127 S San Vicente BlvdPavillion, 7th floorLos Angeles, CA 90048
Phone+1 310-423-5246
Fax+1 310-967-1142

Dr. Prendergast is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Prendergast's full profile Already have an account?

Summary

Dr. Emily Prendergast is an Obstetrics and Gynecology specialist with a subspecialty in Gynecologic Oncology, based in Los Angeles, CA. Educated at the University of Arizona College of Medicine, Dr. Prendergast completed a residency in Obstetrics and Gynecology at McGaw Medical Center of Northwestern University and a fellowship in Gynecologic Oncology at UCLA. Dr. Prendergast currently serves as an Attending Physician in Gynecological Oncology at Cedars Sinai. Previously, Dr. Prendergast worked with Minnesota Oncology, Intermountain Health and the University of Utah. With expertise in chemotherapy, hereditary breast/ovarian cancer, gynecologic oncology, minimally invasive surgery, and clinical research, Dr. Prendergast has published several research articles on these topics, contributing to the fields of gynecologic oncology and early-stage ovarian cancer detection. She currently oversees clinical trials for gynecologic cancer at Samuel Oschin Cancer Center.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gynecologic Oncology, 2014 - 2017
McGaw Medical Center of Northwestern UniversityResidency, Obstetrics and Gynecology, 2010 - 2014
University of Arizona College of MedicineClass of 2010

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

ID State Medical License 2024 - 2029
CA State Medical License 2014 - 2028
UT State Medical License 2022 - 2028
MN State Medical License 2017 - 2027
NV State Medical License 2024 - 2027
IL State Medical License 2013 - 2014
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Publications & Presentations

PubMed

1 citations
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV6...
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk
Future Oncology. 2025-12-01
3 citations
Clinical Evaluation of a Multi-Omic Diagnostic Model for Early-Stage Ovarian Cancer Detection.
Robert A Law, Brendan M Giles, Rachel Culp-Hill, Enkhtuya Radnaa, Mattie Goldberg
Diagnostics. 2025-09-02
27 citations
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk
Journal of Clinical Oncology. 2025-09-01

Press Mentions

More Chemo May Not Equal Better Outcomes in Ovarian CaJanuary 16th, 2017
Hormone Replacement Therapy Improves Bone Mineral Loss After Salpingo-Oophorectomy for Ovarian CancerApril 11th, 2016
Guidelines for Bone Scans After Oophorectomy NeededSeptember 11th, 2017